IMMUNOSIGN®CR enables the measurement of the naturally occurring immune activity in and around the tumor.
This assay has been designed to assess particularly the adaptive immunity and the immune suppression within the tumor microenvironment (TME).
In clinical trials, IMMUNOSIGN®CR can provide prognostic and predictive information for immunotherapies development and guide for combination strategies.
In this study, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.
The treatment is associated with changes in tumor microenvironment that are likely to change the course of the pathology by shifting tumor from a cold state to a hotter immune status even in heavily pretreated patients. This may be particularly useful in patient with “immune-excluded” tumor phenotype as shown on the individual study case.